| TIME | MAY 2, 2019- 2nd İstanbul Immunohematology Summit |
| 08:15-08:30 | Opening Ceremony: Muhlis Cem Ar (TSH General Secretary) |
| 08:30-09:30 | Chair: Osman İlhan (Ankara University, Turkey), Reyhan Küçükkaya (Turkey) |
| 08:30-09:00 |  Innate Immunity: Günnur Deniz (İstanbul University, Turkey) |
| 09:00-09:30 | Acquired Immunity: Safa Barış (Marmara University, Turkey) |
| 09:30-09:45 | Coffee Break |
| 09:45-10:45 | Chair: Yıldız Camcıoğlu (Istanbul University, Turkey) |
| Primary Immune Deficiencies: Elif Aydıner Karakoç (Marmara University, Turkey) |
|
| 10:45-11:00 | Coffee Break |
| 11:00-12:00 | Chair: Tevfik Akoğlu (Marmara University, Turkey) |
| Current Immunotherapies: Meral Beksaç (Ankara University, Turkey) |
|
| 12:00-13:00 | Lunch
|
| TSH/EBMT CTIWP Joint CAR-T Cell Symposium | |
| Chair: Christian Chabannon (Marseille University, France), Güner Hayri Özsan (Dokuz Eylül University, Turkey) | |
| 13:00-13:30 | Regulatory Issues and Standards for CAR-T Cell Administration: Christian Chabannon (Marseille University, France) |
| 13:30-14:00 | Biology of CAR-T Cells: Alvaro Urbano Ispizua (Josep Carreras Leukaemia Research Institue, Spain) |
| 14:00-14:30 | Cell Procurement for CAR-T Cell Manufacturing:Christian Chabannon (Marseille University, France) |
| 14:30-15:00 | Coffee Break |
| Chair: Micha Srour (Institut de Cancérologie de la Loire, France), Mutlu Arat (Florence Nightingale, Turkey) | |
| 15:00-15:30 | Clinical Results of CAR-T Cell in Acute Lymphoblastic Leukemia: Alvaro Urbano Ispizua (Josep Carreras Leukaemia Research Institue, Spain) |
| 15:30-16:00 | Clinical Results of CAR-T Cell in Non Hodgkin Lymphoma: Micha Srour (Institut de Cancérologie de la Loire, France) |
| 16:00-16:30 | Coffee Break |
| Chair: Alvaro Urbano Ispizua (Josep Carreras Leukaemia Research Institue, Spain), Muhit Özcan (Ankara University, Turkey) | |
| 16:30-17:00 | Clinical Results of CAR-T Cell in Multiple Myeloma: Micha Srour (Institut de Cancérologie de la Loire, France) |
| 17:00-17:30 | Qualification of the EBMT Registry by the EMA for CAR-T Cell: Jürgen Kuball (University Medical Center Utrecht, Holland) |
| TIME | MAY 3, 2019 |
| 08:30-10:00 | ACUTE MYELOID LEUKEMIA Scientific Chair: Gert Ossenkoppele (VU University Medical Center , The Netherlands), İnci Alacacıoğlu (Dokuz Eylül University, Turkey) AML Treatment Beyond 3+7: Hartmut Dohner (University Hospital Ulm, Germany) The Emerging Role of MRD in AML: Gert Ossenkoppele (VU University Medical Center, The Netherlands) Immunotherapy in AML: AlloSCT Towards CAR-T Cell Therapy: Marion Subklewe (Ludwig Maximilian University, Germany) |
| 10:00-10:30 | COFFEE BREAK |
| 10:30-12:00 | ACUTE LYMPHOBLASTIC LEUKEMIA Scientific Chair: Dieter Hoelzer (University of Frankfurt, Germany), Teoman Soysal (Istanbul University, Turkey) Progress in T-lineage ALL/TLBL: Renato Bassan ( Ospedale dell’ Angelo e Ss. Giovanni e Paolo, Italy) B-Lineage ALL, Targeted Therapy: Dieter Hoelzer (University of Frankfurt, Germany) Current Status on CAR-T Cells : Álvaro Urbano-Ispizua (Josep Carreras Leukaemia Research Institue, Spain) |
| 12:00-14:00 | LUNCH |
SATELLITE SYMPOSIUM  (12:15-13:15) Scientific Chair: Meral Beksaç (Ankara University, Turkey) Evolving Landscape of Relapsed Multiple Myeloma Treatment with Carfilzomib: Thierry Facon (Lille University Hospital, France) |
|
| 14:00-15:30 | CHRONIC MYELOID LEUKEMIA Scientific Chair: Jane Apperley (Imperial College London, UK), Düzgün Özatlı (Ondokuz Mayıs University, Turkey) Choosing First and Second Line Therapies in the Era of Generic TKI : Tomasz Sacha (Jagiellonian University, Poland) Role of Molecular Monitoring in CML: Jane Apperley (Imperial College London, UK)Considerations for Discontinuing Therapy : Francois Mahon (Institut Bergonié, France) |
| 15:30-16:00 | COFFEE BREAK |
| 16:00-17:00 | ORAL PRESENTATIONS |
| 17:00-17:30 | COFFEE BREAK |
| 17:30-18:30 | MULTIPLE MYELOMA Scientific Chair: Pieter Sonneveld (Erasmus MC, The Netherlands), Ömür Gökmen Sevindik (Medipol University, Turkey) Modern Approaches in Multiple Myeloma Treatment: Pieter Sonneveld (Erasmus MC, The Netherlands)Treatment of Relaps /Refractory Multiple Myeloma: Thierry Facon (Lille University Hospital, France) |
| TIME | MAY 4, 2019 |
| 08:30-10:00 | CHRONIC LYMPHOCYTIC LEUKEMIA Scientific Chair: Anna Schuh (Oxford Molecular Diagnostics Centre, UK), Fatih Demirkan (Dokuz Eylül University, Turkey) Clinical Applications of Prognostic Markers in Chronic Lymphocytic Leukemia: Piers Patten (King’s College Hospital, London)Frontline Therapy of Chronic Lymphocytic Leukemia: Anna Schuh (Oxford Molecular Diagnostics Centre, UK)Treatment of Relapsed Chronic Lymphocytic Leukemia: Anne Quinquenel (Centre Hospitalier Universitaire de Reims, France) |
| 10:00-10:30 | COFFEE BREAK |
| 10:30-12:00 | HODGKIN LYMPHOMA Scientific Chair: Andreas Engert (University Hospital of Cologne, Germany), Ahmet Muzaffer Demir (Trakya University, Turkey) 1st line treatment of HL : Andreas Engert (University Hospital of Cologne, Germany) Nodular Lymphocyte Predominant Hodgkin Lymphoma: Dennis Eichenauer (University of Cologne, Germany)Recent Developments in Relapsed/Refractory Classical Hodgkin Lymphoma: Paul Bröckelmann (University of Cologne, Germany) |
| 12:00-14:00 | LUNCH |
SATELLITE SYMPOSIUM  (12:15-13:15) A New Dimension in Treatment of Relapsed and Refractory Multiple Myeloma: Darzalex ExperiencesScientific Chair: Yıldız Aydın (İstanbul University, Turkey) Speakers: Sevgi Beşışık (İstanbul University, Turkey), Ant Uzay (Acıbadem University, Turkey) |
|
| 14:00-15:30 | INDOLENT LYMPHOMAS Scientific Chair: Eva Kimby (Karolinska Institute, Sweden), Burhan Ferhanoğlu (Koç University, Turkey) Novelties in the Management of Marginal Zone Lymphoma: Catherine Thieblemont (Hospital Saint Louis, France)Follicular Lymphoma – Focus on Therapy: Eva Kimby (Karolinska Institute, Sweden)Cellular Therapies for Follicular Lymphoma: Koen Van Besien (Presbyterian Hospital, USA) |
| 15:30-16:00 | COFFEE BREAK |
| 16:00-17:30 | AGGRESSIVE LYMPHOMAS Scientific Chair: Martin Dreyling (Klinikum der Universität LMU München, Germany), Olga Meltem Akay (Koç University, Turkey) Current Standards in First Line DLBCL: Andrew Davies (University of Southampton, UK)Molecular Subtypes of DLBCL and Clinical Implications: Björn Chapuy (University Medical Center and Comprehensive Cancer Center, Germany)Mantle Cell Lymphoma: Current Standards and Future Study Concepts: Martin Dreyling (Klinikum der Universität LMU München, Germany) |